Meters change from baseline in 6MWD · pulmonary arterial hypertension
1 finding from 1 review
Proportion of participants with improved functional class mean duration of study 16.8 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists probably leads to higher proportion of participants with improved functional class mean… compared with placebo (moderate certainty).
1 finding from 1 review
Change from baseline in BDI mean duration of study 14.3 weeks · pulmonary arterial hypertension
1 finding from 1 review
Mortality mean duration of study 30.2 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in mortality mean duration of study 30.2 weeks compared with placebo (low certainty).
1 finding from 1 review
Change from baseline in mean PAP (mmHg) mean duration of study 17.1 weeks · pulmonary arterial hypertension
1 finding from 1 review
Change from baseline in PVR (dyn/s/cm5) mean duration of study 15.7 weeks · pulmonary arterial hypertension
1 finding from 1 review
Hepatic toxicity mean duration of study 25 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in hepatic toxicity mean duration of study 25 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate may leads to higher all adverse events compared with placebo (low certainty).
1 finding from 1 review
Change in systolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Change in diastolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Change in body weight as compared to placebo (%) from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in total mortality compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in cardiovascular morbidity compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion probably leads to higher all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Change in systolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Change in diastolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review